A Phase 3 Randomized, Double-Blind Study Assessing The Efficacy And Safety Of PF-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms REFLECTIONS B537-02
- Sponsors Pfizer
- 22 Jul 2017 This trial has been completed in Poland (end date: 2017-06-01)
- 17 Jun 2017 This trial has been completed in in Czech republic (end date: 1 Jun 2017) and France (end date: 1 Jun 2017).
- 15 Jun 2017 The study has been completed in Bulgaria (end date: 1 Jun 2017).